Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IF… Read more
Neovacs S.A. (ALNEV) - Total Assets
Latest total assets as of June 2025: €23.07 Million EUR
Based on the latest financial reports, Neovacs S.A. (ALNEV) holds total assets worth €23.07 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neovacs S.A. - Total Assets Trend (2007–2024)
This chart illustrates how Neovacs S.A.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Neovacs S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Neovacs S.A.'s total assets of €23.07 Million consist of 11.4% current assets and 88.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.0% |
| Accounts Receivable | €513.70K | 2.3% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €414.79K | 1.9% |
| Intangible Assets | €441.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Neovacs S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neovacs S.A.'s current assets represent 11.4% of total assets in 2024, a decrease from 90.9% in 2007.
- Cash Position: Cash and equivalents constituted 2.0% of total assets in 2024, down from 55.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 21.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 2.3% of total assets.
Neovacs S.A. Competitors by Total Assets
Key competitors of Neovacs S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Neovacs S.A. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Neovacs S.A. generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Neovacs S.A. is currently not profitable relative to its asset base.
Neovacs S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.67 | 0.67 | 0.27 |
| Quick Ratio | 0.67 | 0.66 | 0.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-1.31 Million | € -1.43 Million | € -3.99 Million |
Neovacs S.A. - Advanced Valuation Insights
This section examines the relationship between Neovacs S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -53.6% |
| Total Assets | €22.07 Million |
| Market Capitalization | $537.87 USD |
Valuation Analysis
Below Book Valuation: The market values Neovacs S.A.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Neovacs S.A.'s assets decreased by 53.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Neovacs S.A. (2007–2024)
The table below shows the annual total assets of Neovacs S.A. from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €22.07 Million | -53.57% |
| 2023-12-31 | €47.53 Million | -3.55% |
| 2022-12-31 | €49.28 Million | +1.51% |
| 2021-12-31 | €48.55 Million | +260.03% |
| 2020-12-31 | €13.49 Million | +78.92% |
| 2019-12-31 | €7.54 Million | +4.12% |
| 2018-12-31 | €7.24 Million | -37.97% |
| 2017-12-31 | €11.67 Million | +25.02% |
| 2016-12-31 | €9.33 Million | -17.05% |
| 2015-12-31 | €11.25 Million | +24.27% |
| 2014-12-31 | €9.05 Million | +18.07% |
| 2013-12-31 | €7.67 Million | +23.45% |
| 2012-12-31 | €6.21 Million | -52.15% |
| 2011-12-31 | €12.98 Million | +21.57% |
| 2010-12-31 | €10.68 Million | +136.05% |
| 2009-12-31 | €4.52 Million | -48.02% |
| 2008-12-31 | €8.70 Million | +117.28% |
| 2007-12-31 | €4.01 Million | -- |